Navidea Biopharmaceuticals Invited to Present Data at Two Major Upcoming Conferences
April 25 2017 - 5:35PM
Business Wire
Navidea invited to present atherosclerosis and
rheumatoid diagnostic imaging data at the Annual Meeting of the
Society of Nuclear Medicine and Molecular Imaging
Navidea selected by the National Institute of
Health/National Institute of Arthritis and Musculoskeletal and Skin
Diseases to present Rheumatoid Arthritis program to investors at
the 2017 BIO International Convention
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) (“Navidea”)
(“the Company”), a company focused on the development and
commercialization of precision immunodiagnostic agents and
immunotherapeutics, today announced that it has been invited to
present data at two major upcoming conferences.
Society of Nuclear Medicine and Molecular Imaging Annual
Meeting
Navidea has been invited to present its Tc99m-tilmanocept
receptor-specific diagnosis data for aortic plaques (Nav/MGH), and
for rheumatoid arthritis (Nav3-21/23), at the Annual Meeting of the
Society of Nuclear Medicine and Molecular Imaging (SNMMI), a
meeting of leading molecular imaging and nuclear medicine experts
representing the world’s top medical and academic institutions and
centers.
Event:
Annual Meeting of the Society of Nuclear Medicine and Molecular
Imaging
Date:
June 10-14, 2017
Time:
June 12, 4:45 - 6:15 PM – Rm 708/710 (Cardio) June 12, 4:45 - 6:15
PM – Rm 603 (Rheumatoid)
Location:
Colorado Convention Center, 700 14th Street, Denver, CO 80202
2017 BIO International Convention
Navidea has been selected by the National Institute of Arthritis
and Musculoskeletal and Skin Diseases (NIAMS), a component of the
National Institute of Health (NIH) to present its Rheumatoid
Arthritis (RA) program to investors at the 2017 BIO International
Convention (BIO 2017). Navidea was selected from more than 1,000
recipients of NIH/NIAMS SBIR grants to present clinical results and
their commercial strategy in regards to the development of
tilmanocept (Tc99m-Tilmanocept), for the diagnostic imaging of
RA.
Event:
2017 Bio International Convention
Date:
June 19-22, 2017
Time:
TBD
Location:
San Diego Convention Center, 111 W. Harbor Drive, San Diego, CA
92101
About
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) is a
biopharmaceutical company focused on the development and
commercialization of precision immunodiagnostic agents and
immunotherapeutics. Navidea is developing multiple
precision-targeted products and platforms including ManoceptTM and
NAV4694 to help identify the sites and pathways of undetected
disease and enable better diagnostic accuracy, clinical
decision-making, targeted treatment and, ultimately, patient care.
Lymphoseek® (technetium Tc99m-tilmanocept) injection was the first
commercial product of the ManoceptTM platform, was approved by the
FDA in March 2013 and in Europe in November 2014. LS North American
rights were sold to Cardinal Health for an upfront payment and
future contingent payments and licensed in Europe to Norgine. The
development activities of the ManoceptTM immunotherapeutic platform
will be conducted by Navidea in conjunction with its subsidiary,
Macrophage Therapeutics. Navidea’s strategy is to deliver superior
growth and shareholder return by bringing to market novel products
and advancing the Company’s pipeline through global partnering and
commercialization efforts. For more information, please visit
www.navidea.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170425006941/en/
Navidea BiopharmaceuticalsJed Latkin (investors &
media)Interim COO & CFOjlatkin@navidea.comorEdison
AdvisorsTirth Patel (investors)tpatel@edisongroup.com
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Apr 2023 to Apr 2024